Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

BSH 2021 | COVID-19 vaccination responses in patients with blood cancers

Paresh Vyas • 27 Apr 2021

BSH 2021

Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia General Leukemia Antibodies Rituximab

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the response to COVID-19 vaccinations in patients with blood cancers. Compared to the general populace, patients with blood cancers will have different responses to vaccinations, and responses will also differ across various blood cancers. Vaccines tend to be less effective in patients with cancers or those receiving immunosuppressive treatments, as well as patients who receive more aggressive chemotherapy treatments. This interview took place at the 2021 British Society for Haematology Annual Scientific Meeting.

Promising emerging therapies for AML and the challenges that remain

Paresh Vyas • 18 Dec 2023

First-in-human study of the menin-KMT2A inhibitor JNJ-75276617 in R/R acute leukemias

Paresh Vyas • 18 Dec 2023

Understanding genetic and non-genetic mechanisms involve in AML disease progression

Paresh Vyas • 24 Apr 2023

Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors

Paresh Vyas • 24 Apr 2023

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024